381 related articles for article (PubMed ID: 15538829)
1. In-vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts.
Quindós G; Ruesga MT; Martín-Mazuelos E; Salesa R; Alonso-Vargas R; Carrillo-Muñoz AJ; Brena S; San Millán R; Pontón J
Rev Iberoam Micol; 2004 Jun; 21(2):63-9. PubMed ID: 15538829
[TBL] [Abstract][Full Text] [Related]
2. [Determination of the in vitro antifungal susceptibility of clinically important yeasts using the Sensititre system].
Carrillo-Muñoz AJ; Quindós G; Gasser I; Tur-Tur C; Ruesga MT; Alonso-Vargas R; Arévalo P; Bornay-Llinares FJ; Santos P; del Valle O
Rev Esp Quimioter; 1999 Jun; 12(2):126-35. PubMed ID: 10562673
[TBL] [Abstract][Full Text] [Related]
3. In vitro antifungal activity of phenylheptatriyne from Bidens cernua L. against yeasts.
Rybalchenko NP; Prykhodko VA; Nagorna SS; Volynets NN; Ostapchuk AN; Klochko VV; Rybalchenko TV; Avdeeva LV
Fitoterapia; 2010 Jul; 81(5):336-8. PubMed ID: 19837144
[TBL] [Abstract][Full Text] [Related]
4. Flucytosine primary resistance in Candida species and Cryptococcus neoformans.
Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Rodríguez-Tudela JL
Eur J Clin Microbiol Infect Dis; 2001 Apr; 20(4):276-9. PubMed ID: 11399020
[TBL] [Abstract][Full Text] [Related]
5. [Molecular epidemiology and antifungal susceptibility of Candida species isolated from urine samples of patients in intensive care unit].
Yüksekkaya S; Fındık D; Arslan U
Mikrobiyol Bul; 2011 Jan; 45(1):137-49. PubMed ID: 21341168
[TBL] [Abstract][Full Text] [Related]
6. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
Ozcan SK; Mutlu B; Dündar D; Willke A
Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
[TBL] [Abstract][Full Text] [Related]
8. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
9. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
10. [In vitro activity of posaconazole against yeasts isolated in blood cultures].
Cantón E; Pemán J; Orero A; Viudes A; Gil J; Rubio MC; Gobernado M
Rev Esp Quimioter; 2002 Dec; 15(4):335-40. PubMed ID: 12587038
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.
Pfaller MA; Messer SA; Boyken L; Huynh H; Hollis RJ; Diekema DJ
Antimicrob Agents Chemother; 2002 Nov; 46(11):3518-21. PubMed ID: 12384359
[TBL] [Abstract][Full Text] [Related]
12. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts.
Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K
Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406
[TBL] [Abstract][Full Text] [Related]
13. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2006 Oct; 44(10):3533-8. PubMed ID: 17021079
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.
Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M
Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period.
Kucukates E; Erturan Z; Susever S; Yegenoglu Y
APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609
[TBL] [Abstract][Full Text] [Related]
16. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method.
Pfaller MA; Barry AL
Mycopathologia; 1995; 130(1):3-9. PubMed ID: 7666925
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts.
Ryder NS; Wagner S; Leitner I
Antimicrob Agents Chemother; 1998 May; 42(5):1057-61. PubMed ID: 9593126
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
Fleck R; Dietz A; Hof H
J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
[TBL] [Abstract][Full Text] [Related]
20. [In vitro activities of posaconazole, fluconazole, itraconazole, ketoconazole and voriconazole against Candida glabrata].
Blanco MT; Cañadas J; García-Martos P; Marín P; García-Tapia A; Rodríguez J
Rev Esp Quimioter; 2009 Sep; 22(3):139-43. PubMed ID: 19662547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
